List view / Grid view
5 March 2018 | By European Pharmaceutical Review
Researchers at the TAT (Targeted Anticancer Therapies) International Congress 2018 in Paris have presented new epigenetics compounds that show early activity in lymphoma patients.
5 October 2016 | By Niamh Louise Marriott, Digital Content Producer
KA2237 is a dual-selective inhibitor of two PI3K isoforms, p110β and p110δ. Inhibiting these two isoforms combines an immunotherapeutic response...
1 August 2016 | By Takeda Pharmaceutical Company Ltd and Seattle Genetics, Inc.
Takeda and Seattle Genetics announce that the ALCANZA trial evaluating ADCETRIS for cutaneous T-cell lymphoma demonstrated significant improvement...
20 July 2016 | By Niamh Louise Marriott, Digital Content Producer
With the EU orhpan drug designations, Cell Medica can now obtain regulatory and financial incentives for developing and marketing CMD-003 as a cancer...
7 December 2015 | By Victoria White
Janssen-Cilag International NV has announced data from the Phase 3 RESONATE-2 (PCYC-1115) trial that show ibrutinib (Imbruvica) was superior to chlorambucil in all efficacy endpoints measured in patients with treatment-naïve chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL) aged 65 or older.
6 February 2015 | By Janssen EMEA
Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved a variation to the terms of the marketing authorisation of VELCADE® (bortezomib) in combination with rituximab, cyclophosphamide, doxorubicin and prednisone for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are unsuitable for blood…
20 October 2014 | By Janssen
Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved IMBRUVICA™ (ibrutinib) capsules, a first-in-class, once-daily, oral Bruton’s tyrosine kinase (BTK) inhibitor.
Send this to a friend
Follow: